Effect of premedication on lesion detection rate and visualization of the mucosa during upper gastrointestinal endoscopy: a multicenter large sample randomized controlled double-blind study

• DOI: 10.1007/s00464-018-6077-4
• Publication Date: 2018-03-23T11:29:49Z
• Authors: X. Liu; C. T. Guan; L. Y. Xue; S. He; Y. M. Zhang; D. L. Zhao; Y. Li; F. G. Liu; J. Li; Y. F. Liu; A. S. Ling; W. Q. Wei; G. Q. Wang
• Keywords: Premedication

Premedication in upper gastrointestinal endoscopy for higher lesions detection rate has not been well studied so far. This study aimed to confirm whether premedication could improve the of early cancer or precancerous and mucosal visibility. From July 2015 December 2015, 7200 participants from 6 centers were screened by with one 4 following premedications randomly: (1) water (group D); (2) pronase A); (3) simethicone B); (4) C). Early rates taken as primary endpoints, visibility was secondary endpoint. They compared among four groups determine different effects terms anatomical sites. Trial registered at Chinese Clinical Registry; registration number is ChiCTR-IOR-17010985. The overall lesion 8.7, 8.4, 10.0, 10.3%, 1.3, 1.4%, 1.5, 1.6%, both without significant difference (p = 0.138 0.878). However, score distributions between control group (D) (A, B, C) all statistically significant, sites p values < 0.001. Subgroup analyses, 2 screening before, also showed esophageal (3.9, 3.3, 4.5, 8.4% 0.004) (7.0, 5.5, 7.3, 12.0% rate. may increase but significantly